JENNA PRANGE: Open Payments
NPI 1467695643 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$368 in 15 payments from 10 companies in 2025. Trend: 2023 $228 · 2024 $94 · 2025 $368
Food & beverage: $368
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 1 | $120 |
| Sumitomo Pharma America, Inc. | 4 | $75 |
| AstraZeneca Pharmaceuticals LP | 3 | $50 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Seqirus USA Inc | 1 | $23 |
| Amgen Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| PFIZER INC. | 1 | $15 |
| Novo Nordisk Inc | 1 | $14 |
| Merck Sharp & Dohme LLC | 1 | $14 |
Products named: EVKEEZA, GEMTESA, OPSUMIT, Fluad, KRYSTEXXA, MOUNJARO, NURTEC ODT, Wegovy.
Industry payments across NE — which companies pay providers there.
